Human dendritic cells in cancer

Kvedaraite, Egle; Ginhoux, Florent

doi:10.1126/sciimmunol.abm9409

Cited by 110 publications

(99 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, we also observed a strong correlation between the proportion of Tregs in T cells from the blood of active LCH patients and plasma Tim-3, that is an emerging immune check point not only in the context of adaptive immune system, but also innate anti-cancer immunity mediated through dendritic cell responses [reviewed in (author?) ( 31 )] ( Figure 1E ).…”

Section: Resultsmentioning

confidence: 99%

Plasma Signaling Factors in Patients With Langerhans Cell Histiocytosis (LCH) Correlate With Relative Frequencies of LCH Cells and T Cells Within Lesions

et al. 2022

Self Cite

View full text Add to dashboard Cite

Langerhans cell histiocytosis (LCH) lesions contain an inflammatory infiltrate of immune cells including myeloid-derived LCH cells. Cell-signaling proteins within the lesion environment suggest that LCH cells and T cells contribute majorly to the inflammation. Foxp3+ regulatory T cells (Tregs) are enriched in lesions and blood from patients with LCH and are likely involved in LCH pathogenesis. In contrast, mucosal associated invariant T (MAIT) cells are reduced in blood from these patients and the consequence of this is unknown. Serum/plasma levels of cytokines have been associated with LCH disease extent and may play a role in the recruitment of cells to lesions. We investigated whether plasma signaling factors differed between patients with active and non-active LCH. Cell-signaling factors (38 analytes total) were measured in patient plasma and cell populations from matched lesions and/or peripheral blood were enumerated. This study aimed at understanding whether plasma factors corresponded with LCH cells and/or LCH-associated T cell subsets in patients with LCH. We identified several associations between plasma factors and lesional/circulating immune cell populations, thus highlighting new factors as potentially important in LCH pathogenesis. This study highlights plasma cell-signaling factors that are associated with LCH cells, MAIT cells or Tregs in patients, thus they are potentially important in LCH pathogenesis. Further study into these associations is needed to determine whether these factors may become suitable prognostic indicators or therapeutic targets to benefit patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Plasma Signaling Factors in Patients With Langerhans Cell Histiocytosis (LCH) Correlate With Relative Frequencies of LCH Cells and T Cells Within Lesions

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“… 12 , 14 Of note, it remains unclear whether DC3 arise from CDPs. 9 , 14 While other cDC2 subsets have been proposed, namely DC4 (CD1C − CD141 − ) and DC5 (AXL + SIGLEC6 + ), 12 their classification within the myeloid population and functional characterization still requires further studies.…”

Section: Introductionmentioning

confidence: 99%

“…It is emerging that cDC2s perform a non-redundant role in mobilizing both CD8 + T cell responses and CD4 + T H cell priming. 9 , 35 , 37 , 38 Moreover, unlike cDC1s, cDC2s can secrete high levels of interleukin-12 (IL-12), 39–41 which is crucial for T and natural killer (NK) cell expansion and survival. 41–43 pDCs excel at type I interferon (IFN) responses, mounting stronger type I IFN responses than any other DC subsets, and being the major producers of IFN-α.…”

Section: Introductionmentioning

confidence: 99%

“… 44–47 Yet, high frequencies of pDCs in the tumor associate with poor prognosis in multiple human cancer types, likely due to frequent impairment of type I IFN production in the TME, leading to immunosuppression. 9 , 48–54 …”

Section: Introductionmentioning

confidence: 99%

“…DCs play a key role in anti-tumor immunity by properly priming CD8 + T cells against tumor-associated or specific antigens (TAAs or TSAs), a process which is often impaired by immunosuppressive TME. 5 , 7 , 9 , 86–90 DCs’ potent antigen presentation and T cell activation ability have made them an important player in anticancer vaccination strategies. 91–95 Classically, DC vaccines in clinical studies are created by ex vivo differentiation of DCs from autologous monocytes obtained from patients with apheresis, followed by exposure to TAAs/TSAs, in the presence of maturation-inducing agents or cocktails, and finally are reinfused back into the same patient.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

et al. 2022

View full text Add to dashboard Cite

Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state of flux toward niche-applications, owing to recent paradigm-shifts in immuno-oncology mobilized by T cell-targeting immunotherapies. DC vaccines are typically generated using autologous (patient-derived) DCs exposed to tumor-associated or -specific antigens (TAAs or TSAs), in the presence of immunostimulatory molecules to induce DC maturation, followed by reinfusion into patients. Accordingly, DC vaccines can induce TAA/TSA-specific CD8 + /CD4 + T cell responses. Yet, DC vaccination still shows suboptimal anti-tumor efficacy in the clinic. Extensive efforts are ongoing to improve the immunogenicity and efficacy of DC vaccines, often by employing combinatorial chemo-immunotherapy regimens. In this Trial Watch, we summarize the recent preclinical and clinical developments in this field and discuss the ongoing trends and future perspectives of DC-based immunotherapy for oncological indications.

show abstract

Nanomaterial‐assisted oncolytic bacteria in solid tumor diagnosis and therapeutics

Zeng,

Chen,

Chen

2024

Bioengineering & Transla Med

View full text Add to dashboard Cite

Cancer presents a formidable challenge in modern medicine due to the intratumoral heterogeneity and the dynamic microenvironmental niche. Natural or genetically engineered oncolytic bacteria have always been hailed by scientists for their intrinsic tumor‐targeting and oncolytic capacities. However, the immunogenicity and low toxicity inevitably constrain their application in clinical practice. When nanomaterials, characterized by distinctive physicochemical properties, are integrated with oncolytic bacteria, they achieve mutually complementary advantages and construct efficient and safe nanobiohybrids. In this review, we initially analyze the merits and drawbacks of conventional tumor therapeutic approaches, followed by a detailed examination of the precise oncolysis mechanisms employed by oncolytic bacteria. Subsequently, we focus on harnessing nanomaterial‐assisted oncolytic bacteria (NAOB) to augment the effectiveness of tumor therapy and utilizing them as nanotheranostic agents for imaging‐guided tumor treatment. Finally, by summarizing and analyzing the current deficiencies of NAOB, this review provides some innovative directions for developing nanobiohybrids, intending to infuse novel research concepts into the realm of solid tumor therapy.

show abstract

Human dendritic cells in cancer

Cited by 110 publications

References 94 publications

Plasma Signaling Factors in Patients With Langerhans Cell Histiocytosis (LCH) Correlate With Relative Frequencies of LCH Cells and T Cells Within Lesions

Plasma Signaling Factors in Patients With Langerhans Cell Histiocytosis (LCH) Correlate With Relative Frequencies of LCH Cells and T Cells Within Lesions

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

Nanomaterial‐assisted oncolytic bacteria in solid tumor diagnosis and therapeutics

Contact Info

Product

Resources

About